Abstract
The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 4909-4911 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 16 |
Issue number | 20 |
DOIs | |
State | Published - Oct 15 2010 |
ASJC Scopus subject areas
- Cancer Research
- Oncology